Vault_Denial_Code,Denial_Reason,Winning_Clinical_Phrases_Universal,Source_Authority,Evidence_Citation,Clinical_Scenario,Bypass_Mechanism,Medications_Applicable,Usage_Notes,Statutory_Blurbs_State_Specific,State
DENY-AI-001,AI/Algorithmic Denial Challenge - Human Review Required,"Pursuant to [STATE STATUTE], denials based solely on artificial intelligence or algorithmic determinations without human clinical review are prohibited. This denial appears to be an automated 'predictive denial' generated without meaningful physician oversight. We demand peer-to-peer review by a licensed physician as required by state law.",State Anti-AI Denial Statutes,NE LB 77 | AL Insurance Dept Policy,Denial appears algorithmic/automated without physician review,Anti-AI Denial / Human Review Requirement,All medications,"Look for signs of automated denial: generic language, no clinical rationale, immediate turnaround, boilerplate text. Challenge if denial lacks individualized medical review.","NE: 'Pursuant to Nebraska LB 77, denials based solely on artificial intelligence or algorithmic determinations are prohibited. This denial appears to be an automated predictive denial without human clinical review. We demand peer-to-peer review by a licensed physician per statute.' | AL: 'Per Alabama Insurance Department guidance, AI-only denials without physician oversight are not valid adverse determinations.'","NE,AL"
DENY-BOTOX-EPISODIC,Botox Denial - Episodic Migraine Not Covered (VALID DENIAL),"This denial is clinically appropriate. OnabotulinumtoxinA (Botox) is FDA-approved ONLY for chronic migraine, defined as headache occurring on ≥15 days per month for >3 months with migraine features on ≥8 days per month (ICHD-3 Section 1.3). Patient has episodic migraine ([X] days/month) and does not meet the FDA-approved indication. Appropriate alternatives for episodic migraine prevention include CGRP monoclonal antibodies (Aimovig, Ajovy, Emgality, Vyepti) and oral gepants (Qulipta, Nurtec ODT), all of which have FDA approval for both episodic and chronic migraine.",FDA Label | ICHD-3 | AHS Consensus 2021,FDA Botox Label Section 1.1 | ICHD-3 Section 1.3 | Ailani J et al. Headache. 2021,Provider education: Botox requested for episodic patient - denial is CORRECT,N/A - This validates denial and redirects to appropriate alternatives,"Botox NOT applicable; Redirect to: Erenumab (Aimovig), Fremanezumab (Ajovy), Galcanezumab (Emgality), Eptinezumab (Vyepti), Atogepant (Qulipta), Rimegepant (Nurtec ODT)","⚠️ THIS IS A VALID DENIAL ACKNOWLEDGMENT - Use to educate providers that Botox denial for episodic patients is correct per FDA label. System should PREVENT Botox selection for episodic patients before PA submission. ICD-10 codes G43.0xx, G43.1xx, G43.8xx = Botox ineligible.",,ALL
DENY-CLUSTER-001,Cluster Headache - Emgality 300mg Medical Necessity,"Patient has been diagnosed with episodic cluster headache per ICHD-3 criteria (Section 3.1.1): severe unilateral orbital, supraorbital, and/or temporal pain lasting 15-180 minutes; ipsilateral autonomic features (conjunctival injection, lacrimation, nasal congestion, rhinorrhea, forehead/facial sweating, miosis, ptosis, eyelid edema); sense of restlessness or agitation; attack frequency of one every other day to eight per day; cluster periods lasting 7 days to 1 year separated by remission periods ≥3 months. Per FDA approval (June 2019) and Goadsby et al. NEJM 2019, galcanezumab (Emgality) 300mg monthly is the only CGRP-targeting therapy FDA-approved for episodic cluster headache prevention.",FDA Label 2019 | ICHD-3 | AHS Cluster Guidelines 2016,Goadsby PJ et al. NEJM 2019;381:132-141. doi:10.1056/NEJMoa1813440,PA request for Emgality 300mg for episodic cluster headache patient,Cluster Headache Diagnosis Documentation,Galcanezumab (Emgality) 300mg - ONLY FDA-approved CGRP for cluster headache,Use ONLY for episodic cluster (G44.011/G44.019). Chronic cluster (G44.02x) NOT FDA-approved. Emgality dose is 300mg for cluster (vs 120mg for migraine).,,ALL
DENY-CLUSTER-002,Cluster Headache - Step Therapy Completion (Verapamil/Lithium),"Patient has completed adequate trials of conventional cluster headache preventive therapies. Patient trialed verapamil at doses up to [X]mg/day with [inadequate efficacy / intolerable adverse effects / ECG abnormalities]. Patient trialed lithium at therapeutic serum levels (0.6-1.2 mEq/L) with [inadequate efficacy / intolerable adverse effects / renal or thyroid concerns]. Per AHS Cluster Headache Guidelines (Robbins et al. Headache 2016), galcanezumab (Emgality) 300mg represents an evidence-based next-line preventive option.",AHS Cluster Headache Guidelines 2016,Robbins MS et al. Headache 2016;56:1093-1106. doi:10.1111/head.12866,PA for Emgality after failure of verapamil and/or lithium,Cluster Preventive Step Therapy Completion,Galcanezumab (Emgality) 300mg,Document doses and durations. For verapamil note ECG monitoring and max dose (up to 960mg/day). For lithium note serum levels. Cluster trials may be 2-4 weeks (shorter than migraine 8 weeks).,,ALL
DENY-CLUSTER-003,Cluster Headache - Verapamil/Lithium Contraindication Bypass,"Patient has documented contraindications to conventional cluster preventives. [For verapamil]: Patient has [sick sinus syndrome / AV block / severe LV dysfunction / hypotension / bradycardia], precluding safe use at therapeutic cluster doses (240-960mg/day). [For lithium]: Patient has [significant renal impairment / lithium-induced thyroid dysfunction / prior toxicity / pregnancy]. Per AHS 2016 Guidelines and FDA approval, Emgality 300mg is indicated for episodic cluster prevention.",AHS Cluster Guidelines 2016 | FDA Label 2019,Robbins MS et al. Headache 2016;56:1093-1106 | FDA Emgality Label,Episodic cluster patient who cannot take verapamil or lithium,Verapamil/Lithium Contraindication Bypass,Galcanezumab (Emgality) 300mg,"Document specific contraindication with evidence (ECG, labs). Bypasses step therapy like migraine CV bypass for triptans.",,ALL
DENY-CLUSTER-004,Chronic Cluster Headache - Off-Label Emgality Appeal,"Patient has refractory chronic cluster headache per ICHD-3 (Section 3.1.2): attacks for ≥1 year without remission or remissions <3 months. While galcanezumab did not meet primary endpoint in Phase 3 chronic cluster trial (Dodick et al. Cephalalgia 2020), real-world evidence demonstrates meaningful response in selected refractory patients. Patient has exhausted all conventional options. Given severity and lack of FDA-approved alternatives for chronic cluster, off-label galcanezumab 300mg is medically necessary.",ICHD-3 | Real-World Evidence,Dodick DW et al. Cephalalgia 2020;40:935-948 | Ruscheweyh R et al. Cephalalgia 2020;40:1574-1584,Refractory chronic cluster patient seeking off-label Emgality,Off-Label Medical Necessity for Refractory Chronic Cluster,Galcanezumab (Emgality) 300mg - OFF-LABEL for chronic cluster,⚠️ HIGH DENIAL RISK. Chronic cluster (G44.02x) NOT FDA-approved. Phase 3 failed. Use only for truly refractory patients. Expect denial; prepare for peer-to-peer.,,ALL
DENY-CLUSTER-005,Cluster Headache - Wrong Diagnosis Code Correction,"This PA request is for cluster headache, NOT migraine. Patient has trigeminal autonomic cephalalgia characterized by: strictly unilateral pain; attack duration 15-180 minutes (vs migraine 4-72 hours); prominent autonomic features; circadian rhythmicity; restlessness during attacks. ICD-10 must be G44.01x (episodic) or G44.02x (chronic), NOT G43.xxx. Please process under cluster headache criteria: step therapy is verapamil/lithium (not beta-blockers/TCAs); medication is Emgality 300mg (not other CGRPs).",ICHD-3 Diagnostic Criteria,ICHD-3 Section 3.1 vs Section 1,PA denied because migraine criteria applied to cluster patient,Diagnosis Correction - Cluster vs Migraine,Galcanezumab (Emgality) 300mg,"Use when payer applied migraine PA criteria to cluster request. Clarify ICD-10, step therapy, and medication differences.",,ALL
DENY-CLUSTER-006,Cluster Headache Acute - High-Flow Oxygen Medical Necessity,"Patient requires home high-flow oxygen for acute cluster attack abortion. Per AHS Guidelines (Robbins et al. Headache 2016), high-flow oxygen at 12-15 L/min via non-rebreather mask is Level A evidence for cluster acute treatment with 78% response rate (Cohen et al. JAMA 2009). Patient experiences [X] attacks per [day/week]. Oxygen is non-pharmacological, has no medication overuse risk, and prevents ED utilization.",AHS Cluster Guidelines 2016 | Level A Evidence,Cohen AS et al. JAMA 2009;302:2451-2457,PA for home oxygen equipment for cluster headache,Cluster Acute Treatment - Oxygen,High-flow oxygen 12-15 L/min; E-cylinder tanks; non-rebreather mask,Often DME benefit not pharmacy. Document attack frequency. Fire safety counseling required.,,ALL
DENY-CONT-001,Continuity of Care - Plan Transition Protection,"Pursuant to [STATE STATUTE], the insurer is statutorily mandated to honor the prior authorization granted by [Previous Insurer] for a minimum of 90 days during plan transition. The patient is stable on this therapy and has been receiving it under continuous prior authorization. Discontinuation or demand for step therapy restart constitutes a violation of state law regarding continuity of care for patients in an active course of treatment.",State Continuity of Care Statutes,MT SB 449 | ME 24-A MRSA §4304-B | VT Act 111 | WY statute | AR Act 97,Patient switching plans; previous PA should be honored,Continuity of Care / Plan Transition Protection,All medications with active PA from previous plan,Obtain copy of previous PA approval letter. Submit Continuity of Care request BEFORE first refill needed under new plan.,"MT: 'Pursuant to Montana SB 449 (2025), the insurer must honor the prior authorization granted by [Previous Insurer] for 90 days minimum.' | ME: 'Pursuant to Maine 24-A MRSA §4304-B, the carrier cannot restrict coverage for this prescription approved by the previous carrier for at least 90 days.' | VT: 'Pursuant to Vermont Act 111, new insurer must honor previous approval for 90 days if patient is stable.' | AR: 'Pursuant to Arkansas Act 97, step therapy from previous plan must be honored; cannot restart step therapy.'","MT,ME,VT,WY,AR,OK,MS,AK"
DENY-DUAL-001,Dual Therapy - OnabotulinumtoxinA Plus CGRP mAb,"In patients with intractable chronic migraine already receiving OnabotulinumtoxinA (Botox), the addition of a CGRP monoclonal antibody has been observed to improve treatment response. The combination extended therapeutic effects by approximately 2 weeks compared to OnabotulinumtoxinA monotherapy. Differential effects on the trigeminovascular system suggest synergistic capability between the two modalities, with good tolerability and safety. This patient meets criteria for treatment-refractory chronic migraine and requires combination therapy.",AHS Consensus Statement 2021,Ailani J et al. Headache. 2021;61(7):1021-1039. doi:10.1111/head.14153,Patient with chronic migraine on Botox with suboptimal response; requesting addition of CGRP mAb,Synergistic mechanism for refractory chronic migraine,OnabotulinumtoxinA (Botox) + Erenumab (Aimovig) OR Fremanezumab (Ajovy) OR Galcanezumab (Emgality),"Use for chronic migraine (≥15 headache days/month per ICHD-3) with documented partial response to Botox. Document baseline headache frequency, Botox response, and functional impairment scores (MIDAS/HIT-6).",,ALL
DENY-EPISODIC-001,Episodic Migraine Diagnosis Statement,"Patient has been diagnosed with episodic migraine per ICHD-3 criteria (Section 1.1/1.2): at least 5 attacks with headache lasting 4-72 hours; at least 2 of unilateral location, pulsating quality, moderate-severe intensity, or aggravation by physical activity; with nausea/vomiting or photophobia and phonophobia. Patient experiences [X] migraine days per month, which is below the chronic migraine threshold (≥15 days/month) but causes substantial functional impairment warranting preventive therapy.",ICHD-3 (2018) | AHS Consensus 2021,"ICHD-3 Section 1.1, 1.2 | Ailani J et al. Headache. 2021;61(7):1021-1039",PA request for episodic migraine patient (4-14 days/month); establishing diagnosis for CGRP mAb or gepant preventive therapy,Episodic Migraine Diagnosis Documentation,"Erenumab (Aimovig), Fremanezumab (Ajovy), Galcanezumab (Emgality), Eptinezumab (Vyepti), Atogepant (Qulipta), Rimegepant (Nurtec ODT preventive)","Use instead of chronic migraine language when patient has 4-14 migraine days/month. Fill in [X] with actual monthly migraine days from headache diary. ICD-10: G43.009, G43.019, G43.109, G43.119. Do NOT use G43.7xx (chronic) codes.",,ALL
DENY-EPISODIC-002,High-Frequency Episodic Migraine - Preventive Indication,"Patient has high-frequency episodic migraine per ICHD-3, experiencing [8-14] migraine days per month. Per AHS 2024 Consensus Statement and ACP 2025 Guidelines, patients with ≥4 migraine days per month who experience functional impairment are candidates for preventive therapy. High-frequency episodic migraine (8-14 days/month) carries significant risk of progression to chronic migraine if undertreated. Early initiation of CGRP-targeting preventive therapy is medically necessary to reduce attack frequency, prevent chronification, and restore functional capacity.",AHS Position Statement 2024 | ACP Guidelines 2025 | ICHD-3,Charles AC et al. Headache. 2024;64(4):333-341 | ACP Ann Intern Med. 2025;178:369-380,PA request for high-frequency episodic patient (8-14 days/month) where payer may argue patient does not meet chronic threshold,High-Frequency Episodic Preventive Indication,"Erenumab (Aimovig), Fremanezumab (Ajovy), Galcanezumab (Emgality), Atogepant (Qulipta)","Use when payer questions medical necessity for episodic patients approaching chronic threshold. Document: (1) Monthly migraine days from diary, (2) MIDAS ≥11 or HIT-6 ≥50, (3) Risk of chronification. Complements DENY-QL-001 for quantity limit scenarios.",,ALL
DENY-EPISODIC-003,Episodic Migraine - Acute Gepant After Triptan Failure,"Patient has episodic migraine with documented inadequate response to acute triptan therapy. Patient has trialed [triptan 1] and [triptan 2] with [inadequate pain relief within 2 hours / recurrence requiring re-dosing / intolerable adverse effects]. Per AHS 2018 Position Statement and ACP 2025 Guidelines, CGRP receptor antagonists (gepants) represent an appropriate next-line acute therapy for patients who have failed or cannot tolerate triptans. Unlike triptans, gepants do not cause vasoconstriction and do not carry the same medication overuse headache risk profile.",AHS Position Statement 2018 | ACP Guidelines 2025,American Headache Society. Headache. 2019;59(1):1-18 | ACP Ann Intern Med. 2025;178:369-380,PA request for acute gepant (Ubrelvy/Nurtec/Zavzpret) for episodic patient after triptan failures,Acute Gepant Access After Triptan Step Therapy Completion,"Ubrogepant (Ubrelvy), Rimegepant (Nurtec ODT acute), Zavegepant (Zavzpret)","Document specific triptans failed and reason for failure. This phrase is for ACUTE gepant use (PRN dosing), not preventive. Complements DENY-STEP-001 which focuses on CV bypass for patients who cannot try triptans. ICD-10: G43.009, G43.019, G43.109, G43.119.",,ALL
DENY-FIRST-001,First-Line CGRP Therapy Without Step Therapy,"The CGRP-targeting migraine therapies are a first-line option for migraine prevention. Initiation of these therapies should not require trial and failure of non-specific migraine preventive medication approaches. CGRP is established as a fundamental mechanism of migraine, making CGRP-targeting therapies 'migraine-specific' in contrast to all other established therapies developed for other indications (hypertension, depression, epilepsy). The cumulative evidence for efficacy, safety, and tolerability of CGRP-targeting therapies is significantly greater than that for any established migraine preventive therapy.",AHS Position Statement 2024,Charles AC et al. Headache. 2024;64(4):333-341. doi:10.1111/head.14692 | VERBATIM,Requesting CGRP mAbs or gepants as initial preventive therapy without prior oral preventive trials,AHS 2024 First-Line Position Statement,"Erenumab (Aimovig), Fremanezumab (Ajovy), Galcanezumab (Emgality), Eptinezumab (Vyepti), Atogepant (Qulipta), Rimegepant (Nurtec ODT for prevention)",Cite AHS 2024 Position Statement directly. Use in conjunction with state-specific statutory language where Gold Card or step therapy reform laws exist.,,ALL
DENY-FIRST-002,First-Line CGRP - State Payer Policy (No Step Required),"This payer has adopted a first-line CGRP policy eliminating oral preventive step therapy requirements for migraine prevention. Per [PAYER] policy update effective [DATE], CGRP-targeting therapies are approved as first-line for [episodic/chronic] migraine without requiring failure of non-specific oral preventives. This aligns with the 2024 AHS Position Statement recognizing CGRPs as first-line options.",Payer-Specific Policies,WV Highmark Oct 2025 | LA BCBSLA 2026 | ND BCBSND Jan 2026 (Chronic only),Requesting CGRP at payer that has adopted first-line policy,Payer-Specific First-Line CGRP Policy,"Erenumab (Aimovig), Fremanezumab (Ajovy), Galcanezumab (Emgality), Atogepant (Qulipta)",Verify payer policy is current. Note: ND BCBSND first-line is for CHRONIC migraine only (≥15 days/month); episodic still requires step therapy.,"WV: 'Per Highmark BCBS WV policy effective October 2025, CGRP mAbs are approved first-line for migraine prevention without oral step therapy.' | LA: 'Per BCBSLA 2026 formulary update, CGRP therapies are first-line for migraine.' | ND: 'Per BCBSND January 2026 Policy Update, CGRP-targeting therapies are first-line for CHRONIC migraine without oral preventive step therapy.'","WV,LA,ND"
DENY-FORM-001,Non-Preferred Agent Denial - Formulary Tier Exception Request,"The payer has classified the requested medication as Non-Preferred or placed it on a higher formulary tier (Tier 4/Specialty). The patient has documented clinical failure of, intolerance to, or contraindication to the payer's preferred formulary alternatives. Under 42 CFR §423.578 (Medicare Part D) and applicable state formulary exception laws, the patient is entitled to a Tier Exception when the preferred agent is medically inappropriate. The requested agent is the standard of care per the 2024 AHS Consensus Statement. The higher cost-sharing associated with the Non-Preferred tier creates a significant barrier to adherence, which is expected to worsen clinical outcomes including increased emergency department utilization and functional disability as measured by MIDAS/HIT-6 scores.",AHS Consensus 2021/2024 | 42 CFR §423.578 | CMS Medicare Part D Coverage Determination,Ailani J et al. Headache. 2021;61(7):1021-1039. | Charles A. Headache. 2024;64:333-342. | 42 CFR §423.578(a) - Coverage Determination for Tiered Cost-Sharing Exception,"Requested drug is Non-Preferred/Tier 4+ on payer formulary. Patient has failed, is intolerant to, or has contraindication to the preferred alternatives on the same formulary. Database G identifies preferred alternatives by Vault_Payer_ID for targeted language.",Tier Exception / Formulary Exception Request,"Qulipta (87% Non-Preferred), Vyepti (70% Non-Preferred), Ubrelvy (36%), Ajovy (30%), Nurtec ODT (26%), Aimovig (15%)","CRITICAL: Use Database G to identify the payer's SPECIFIC preferred agents before writing appeal. Example: If payer prefers Aimovig/Emgality, document failure of THOSE SPECIFIC agents. Do NOT generically say ""failed CGRPs"" — name the payer's preferred drugs by name. For Medicare Part D: Cite 42 CFR §423.578. For Commercial: Cite state formulary exception statute if available.",,ALL
DENY-FORM-002,Formulary Exclusion Denial - Non-Formulary Exception Request,"The payer has placed the requested medication on the Exclusion List / Non-Formulary status for the current plan year. However, this patient has a documented medical necessity for this specific agent that cannot be met by any formulary alternative. The patient has trialed and failed the payer's preferred agents [SPECIFY FROM DATABASE G] with documented adverse events or inadequate therapeutic response. Federal law (42 CFR §423.578 for Part D) and state law require payers to maintain an exceptions process for excluded medications when medical necessity is demonstrated. Denial of this exception forces the patient to use clinically inappropriate alternatives, violating the standard of care established by the 2024 American Headache Society Consensus Statement.",AHS Consensus 2024 | 42 CFR §423.578 | State Formulary Exception Statutes,Charles A. Headache. 2024;64:333-342. | 42 CFR §423.578(b) - Request for Exception to Formulary | CMS Medicare Prescription Drug Benefit Manual Ch. 18 §50.4,"Drug is excluded from formulary entirely. Most commonly: Ajovy (19 payers exclude), Aimovig (excluded by Point32Health, Blue KC). Patient is stable on excluded agent from prior plan year or prior payer. Forced switch risks clinical destabilization.",Non-Formulary Exception / Medical Necessity Override,"Ajovy (excluded at 19 payers incl. UHC in multiple states, Harvard Pilgrim), Aimovig (excluded at Point32Health MA, Blue KC KS), Emgality (excluded at Blue KC MO, MO Anthem)","For EXCLUDED drugs, the appeal bar is higher than Non-Preferred. Must demonstrate: (1) Failure of ALL formulary alternatives, not just preferred ones; (2) Unique clinical characteristic requiring THIS specific agent (e.g., Ajovy quarterly dosing for adherence, Aimovig receptor-blocking vs ligand-binding mechanism); (3) Risk of destabilization if switched. Pair with DENY-CONT-001 (Continuity of Care) if patient was stable on agent under prior plan.",,ALL
DENY-FORM-003,Step-Within-Class Denial - Preferred CGRP Agent Required Before Non-Preferred,"The payer requires failure of a preferred CGRP agent before authorizing the requested non-preferred CGRP. The patient has documented clinical failure of the payer's preferred CGRP agent(s) [SPECIFY: e.g., Aimovig 140mg x 3 months with <30% MMD reduction; Emgality 120mg x 3 months with inadequate response]. The CGRP monoclonal antibodies, while sharing the same target pathway, have distinct pharmacological mechanisms: Erenumab (Aimovig) is a CGRP receptor antagonist, while Fremanezumab (Ajovy) and Galcanezumab (Emgality) are CGRP ligand-binding antibodies. Failure of one mechanism does not predict failure of the other. The 2024 AHS Consensus Statement supports switching between CGRP mechanisms for non-responders.",AHS Consensus 2021/2024 | ACP Guidelines 2025,Ailani J et al. Headache. 2021;61(7):1021-1039. | Charles A. Headache. 2024;64:333-342. | Overeem LH et al. J Headache Pain. 2022;23(1):106 (switching CGRP mAbs efficacy),"Payer requires Aimovig or Emgality (preferred) before Ajovy, Qulipta, or Vyepti (non-preferred). Patient has failed the preferred agent. Database G Step_Within_Class field identifies the specific step-within-class requirements per payer (55 payers require ""Fail Aimovig first"", 22 require step within Ajovy/Emgality class, etc.).",Intra-Class Switch / Mechanism-of-Action Difference,"Ajovy (54 payers require step-within-class), Emgality (77 payers), Aimovig (44 payers), Vyepti (20 payers), Qulipta (21 payers)","KEY DISTINCTION: This code is for step-within-CGRP class (preferred→non-preferred CGRP), NOT for the initial step therapy requiring oral preventive failure (use DENY-STEP-001 through DENY-STEP-005 for those). Document: (1) Which preferred CGRP was tried; (2) Dose and duration (≥3 months at therapeutic dose); (3) Quantified response (<30% MMD reduction = inadequate); (4) Why the requested non-preferred agent is mechanistically different.",,ALL
DENY-FORM-004,Site-of-Care Denial - Vyepti/Botox Administration Setting Restriction,"The payer has denied coverage based on the site of administration (e.g., requiring home infusion instead of HOPD, or denying office-based administration). The patient requires administration in the requested setting due to [SPECIFY: history of infusion reaction requiring medical monitoring, difficult IV access requiring experienced staff, complex comorbidities requiring physician supervision, geographic inaccessibility of alternative settings, or needle phobia/inability to self-inject requiring supervised administration]. Site-of-care steering that ignores individual patient clinical needs violates the medical necessity standard. The prescribing physician has determined that the requested setting is the safest and most clinically appropriate for this patient.",AHS Consensus 2021 | CMS Site-of-Service Policy | State Patient Protection Statutes,Ailani J et al. Headache. 2021;61(7):1021-1039. | Dodick DW et al. Neurology. 2021;96(7):e1126-e1138 (Vyepti PROMISE trials) | CMS MLN Matters SE18023 - Medicare Site-of-Service Differential,"Vyepti (eptinezumab) or Botox (onabotulinumtoxinA) denied based on site of care. Common scenarios: (1) HOPD denied in favor of home infusion/freestanding center; (2) Office administration denied; (3) Infusion center required but patient needs hospital setting. Database G Site_of_Care field shows: 106 payers restrict Vyepti to Physician Office, 41 require Home Infusion, 7 have HOPD restrictions.",Medical Necessity for Specific Administration Setting,"Eptinezumab (Vyepti) - IV infusion J3032, OnabotulinumtoxinA (Botox) - physician-administered J0585","SITE-OF-CARE denials are INCREASING in 2026. Key arguments by setting: HOPD needed: ""History of infusion reaction / difficult IV access / complex comorbidities."" Office needed: ""Patient requires direct physician supervision during administration."" Home infusion needed: ""Patient is homebound / severe disability / transportation barriers."" IMPORTANT: If payer steers to home infusion, verify patient has adequate home setup. Pair with DENY-NEEDLE-001 when needle phobia is the driver for Vyepti over SC CGRPs.",,ALL
DENY-FORM-005,Quantity Limit Exception - Acute Migraine Medication QL Override,"The payer's quantity limit of [SPECIFY: e.g., 8 tablets/30 days for Nurtec, 16 tablets/30 days for Ubrelvy] is clinically insufficient for this patient's documented migraine frequency. The patient experiences [X] migraine days per month, requiring acute treatment on each attack day per clinical guidelines. The AHS and ACP guidelines recommend treatment of each individual attack; undertreating acute episodes increases the risk of chronification and medication overuse headache. The prescribing frequency is consistent with the FDA-approved dosing (Nurtec: 75mg as needed, max 1/day; Ubrelvy: 50-100mg, may repeat x1 after 2 hours). This quantity limit override is medically necessary to provide adequate acute migraine coverage and prevent progression to chronic daily headache.",AHS Consensus 2021 | ACP Guidelines 2025 | FDA Prescribing Information,"Ailani J et al. Headache. 2021;61(7):1021-1039. | ACP Clinical Guideline. Ann Intern Med. 2025. | Nurtec ODT PI: 75mg as needed, max 1/day. | Ubrelvy PI: 50-100mg, may repeat x1 after 2h, max 200mg/day",Payer imposes quantity limit on acute migraine medication below clinical need. Common QLs from Database G: Nurtec ODT 8/30 days (176 payers) or 16/30 days (105 payers); Ubrelvy 16/30 days (177 payers) or 10/30 days (45 payers). Patient with high-frequency episodic (8-14 MMD) or chronic migraine (≥15 MMD) needs more.,Quantity Limit Exception / Medical Necessity Override,"Rimegepant (Nurtec ODT) - QL typically 8-16/30d, Ubrogepant (Ubrelvy) - QL typically 10-16/30d, Atogepant (Qulipta) - QL typically 30/30d","PAIR WITH DENY-QL-001 (existing code for general QL override). This code is specific to formulary-driven QLs that are lower than FDA-approved usage. Document: (1) Monthly migraine day count from headache diary; (2) Current QL is insufficient (e.g., 8 tabs for 12 MMD patient); (3) Risk of undertreating: MOH progression, ED visits, missed work; (4) FDA label allows daily use for Nurtec (max 75mg/day).",,ALL
DENY-FORM-006,Formulary Change / Non-Medical Switching - Continuity of Care Defense,"The patient has been clinically stable on the requested medication for [X] months under their current or previous health plan. The payer's formulary change for the 2026 plan year has reclassified this medication as Non-Preferred, Excluded, or removed from the formulary. Forced switching to a different agent when the patient is clinically stable constitutes non-medical switching, which is prohibited or restricted under [STATE STATUTE] and violates continuity of care protections. The 2021 AHS Consensus Statement warns that switching stable migraine patients between CGRP therapies risks clinical destabilization, loss of therapeutic response, and regression to higher migraine frequency. The biological washout period for CGRP mAbs (5 half-lives = 5-7 months) means any switch carries significant risk of uncontrolled migraines during the transition period.",AHS Consensus 2021 | State Non-Medical Switching Laws | 42 CFR §423.120(b)(5),Ailani J et al. Headache. 2021;61(7):1021-1039. | 42 CFR §423.120(b)(5) - Transition Process for Part D | CMS Medicare Prescription Drug Benefit Manual Ch. 6 §30.4.3 (Transition Policy),"Patient stable on a CGRP medication that was reclassified in 2026 formulary update. Most common: Ajovy moved to Excluded (19 payers), plan transitions from one PBM to another (e.g., CVS Caremark → Express Scripts swap). Patient faces immediate non-formulary rejection.",Continuity of Care Exception / Transition Supply / Non-Medical Switching Defense,"All CGRP mAbs (Aimovig, Emgality, Ajovy), Gepants (Nurtec, Ubrelvy, Qulipta), OnabotulinumtoxinA (Botox) - any agent affected by formulary reclassification",PAIR WITH DENY-SWITCH-001 (existing non-medical switching code) and DENY-CONT-001 (continuity of care). This code adds the FORMULARY-SPECIFIC context from Database G. For Medicare Part D: CMS requires a minimum 90-day transition supply for new enrollees. For Commercial: Check Database F for state-specific non-medical switching laws. KEY: File within 30-60 days of plan effective date to invoke transition protections. Document: (1) Duration of stability on current agent; (2) Specific formulary change; (3) MMD reduction achieved; (4) Risk of destabilization with switch.,,ALL
DENY-FORM-007,IV CGRP (Vyepti) Step-Within-Class - SC CGRP Failure Required Before IV,"The payer requires failure of subcutaneous self-injectable CGRP mAb(s) before authorizing IV eptinezumab (Vyepti). The patient has documented failure of [SPECIFY SC CGRP from Database G preferred list] with inadequate therapeutic response (MMD reduction <30% after ≥3 months at therapeutic dose). Alternatively, the patient has a documented inability to self-administer subcutaneous injections due to [needle phobia / dexterity impairment / cognitive limitations / caregiver unavailability]. IV eptinezumab offers a distinct pharmacological profile: (1) 100% bioavailability via IV route; (2) rapid onset within 1 day of infusion (vs. weeks for SC agents); (3) quarterly dosing reduces adherence burden; (4) physician-supervised administration ensures compliance. Per the AHS 2021 Consensus Statement, route of administration should be individualized based on patient needs.",AHS Consensus 2021/2024 | FDA Prescribing Information - Vyepti,"Ailani J et al. Headache. 2021;61(7):1021-1039. | Dodick DW et al. Neurology. 2021;96(7):e1126-e1138 (PROMISE-1 & PROMISE-2 trials) | Vyepti (eptinezumab-jjmr) Prescribing Information, Lundbeck 2025","Vyepti requires step through SC CGRP at 20 payers. Step requirements include: ""Fail SC CGRP before Vyepti"" (2 payers), ""Fail Aimovig/Emgality before Vyepti"" (1 payer), ""Fail injectable CGRP first"" (4 payers). Total Vyepti records with step-within-class: 20.",SC CGRP Failure Documentation / Needle Phobia / Self-Administration Inability,Eptinezumab (Vyepti) 100mg or 300mg IV infusion - J3032,"Vyepti has TWO distinct denial pathways — this code covers the step-within-class requirement (fail SC before IV). For site-of-care issues use DENY-FORM-004. For needle phobia driving Vyepti choice over SC CGRPs, PAIR with DENY-NEEDLE-001. Document: (1) Which SC CGRPs were tried and results; (2) Duration and dose of each trial; (3) Why IV is specifically needed. Note: 70% of payers classify Vyepti as Non-Preferred — may also need DENY-FORM-001.",,ALL
DENY-GOLD-001,Gold Card Exemption - Provider Qualifies for PA Waiver,"Pursuant to [STATE STATUTE], this practice has achieved a prior authorization approval rate exceeding 90% for the requested service/medication class over the preceding evaluation period. The provider is therefore exempt from prior authorization requirements under the state's Gold Card law. This request should be processed without PA review. Denial of this claim constitutes a violation of state insurance law.",State Gold Card Statutes,TX HB 3459 | WV HB 4102 | ND SB 2280 | VT Act 111 | AR Act 575 | GA SB 5 | WY W.S. § 26-55-112,Provider meets Gold Card threshold; asserting exemption from PA,Gold Card / PA Exemption Statute,All medications where provider has demonstrated 90%+ approval rate,"Document provider approval rate data. Note: Many states EXCLUDE pharmacy benefits from Gold Card (WY, AR, MO). Check state-specific exclusions before asserting.","TX: 'Pursuant to Texas Insurance Code § 4201.659 (HB 3459), this provider has achieved Gold Card status with >90% approval rate and is exempt from PA for this service.' | WV: 'Pursuant to West Virginia HB 4102, this provider qualifies for Gold Card exemption.' | ND: 'Pursuant to North Dakota SB 2280, Gold Card exemption is asserted.' | VT: 'Pursuant to Vermont Act 111, this provider is exempt from PA requirements.' | GA: 'Pursuant to Georgia SB 5, Gold Card exemption applies.'","TX,WV,ND,VT,AR,GA,WY,PA,CA,DE,MN"
DENY-GOLD-002,Gold Card Pharmacy Exclusion - Medical Benefit Exception,"While [STATE] Gold Card law excludes pharmacy benefit drugs, this request is for a MEDICAL BENEFIT service (J-code administration). The Gold Card exemption applies to medical services and procedures. This Botox administration (J0585) or Vyepti infusion (J3032) qualifies for Gold Card exemption under the medical benefit carve-out.",State Gold Card Statutes with Pharmacy Exclusions,WY W.S. § 26-55-112 | AR Act 575 | MO HB 618,Provider asserting Gold Card for medical benefit J-code when pharmacy is excluded,Medical Benefit J-Code Exception to Pharmacy Exclusion,"OnabotulinumtoxinA (Botox J0585), Eptinezumab (Vyepti J3032), IV infusion services",Use in states where Gold Card explicitly excludes pharmacy but provider qualifies for medical services. Focus on administration codes (CPT 64615) and drug J-codes.,"WY: 'Per W.S. § 26-55-112, pharmacy benefits are excluded from Gold Card. However, this medical benefit administration (J0585/CPT 64615) qualifies for exemption.' | AR: 'Per Act 575, Gold Card applies to medical PAs; this J-code service qualifies.'","WY,AR,MO"
DENY-HEMI-001,Hemiplegic/Basilar Migraine - Triptan Contraindication,Patient has diagnosis of hemiplegic migraine (G43.4) or migraine with brainstem aura/basilar migraine (G43.1). Triptans are CONTRAINDICATED in these migraine subtypes per FDA labeling due to theoretical risk of stroke. This contraindication is absolute and not subject to step therapy override. Gepants (Nurtec/Ubrelvy) or ditans (Reyvow) are medically necessary as first-line acute treatment.,FDA Triptan Labels | AHS Consensus 2021,All triptan FDA package inserts contain hemiplegic/basilar contraindication,Patient with hemiplegic or basilar migraine requesting gepant/ditan without triptan trial,Absolute Contraindication - Hemiplegic/Basilar Migraine,"Rimegepant (Nurtec ODT), Ubrogepant (Ubrelvy), Lasmiditan (Reyvow)","ICD-10: G43.4 (Hemiplegic migraine), G43.1 (Migraine with aura). Document migraine subtype in chart. This is an ABSOLUTE bypass - no triptan trial should ever be attempted.",,ALL
DENY-MOH-001,Medication Overuse Headache - CGRP Access Justification,"Patient has documented Medication Overuse Headache (MOH) per ICHD-3 criteria (Section 8.2): headache occurring ≥15 days/month in a patient with pre-existing primary headache disorder, developing as a consequence of regular overuse of acute headache medication for >3 months. Patient has documented use of [simple analgesics ≥15 days/month OR combination analgesics/triptans ≥10 days/month]. Per AHS 2021 Consensus Statement, CGRP-targeting therapies are particularly appropriate for patients with MOH because these medications ""do not appear to cause or worsen medication overuse headache"" and have demonstrated efficacy in MOH populations. Gepants and CGRP monoclonal antibodies offer a therapeutic advantage over traditional preventives by providing effective prevention without contributing to the medication overuse cycle.",ICHD-3 Section 8.2 | AHS 2021 Consensus Statement,"Ailani J et al. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021-1039. | Diener HC et al. Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol. 2016;12:575-583.",Patient with chronic headache and documented overuse of OTC analgesics or triptans seeking CGRP therapy,MOH Documentation Supporting CGRP Access,"All CGRP mAbs (Aimovig, Ajovy, Emgality, Vyepti), All Gepants (Qulipta, Nurtec ODT)","Document specific medications overused and frequency. Simple analgesics (acetaminophen, NSAIDs, aspirin) require ≥15 days/month. Combination analgesics with caffeine (Excedrin), triptans, ergots, and opioids require only ≥10 days/month. Headache diary data strengthens this appeal. ICD-10: G44.41.",,ALL
DENY-NEEDLE-001,Needle Phobia / Dexterity Impairment - Vyepti Medical Necessity,"Patient has documented needle phobia (DSM-5 Specific Phobia, Blood-Injection-Injury Type) or dexterity/cognitive impairment preventing self-injection. The preferred self-injectable CGRP mAbs (Aimovig, Ajovy, Emgality) are not feasible administration routes for this patient. Intravenous administration via Vyepti (eptinezumab) is medically necessary as an ADA/Section 1557 accommodation to ensure equitable access to CGRP-targeting therapy.",AHS Consensus 2021 | ADA/Section 1557,Ailani J et al. Headache. 2021;61(7):1021-1039.,Patient cannot self-inject; requesting Vyepti instead of SC CGRP mAbs,Needle Phobia / Dexterity Accommodation,Eptinezumab (Vyepti),"Document DSM-5 diagnosis of Specific Phobia (Blood-Injection-Injury type) or document dexterity impairment (arthritis, tremor, cognitive impairment). Consider also: severe injection site reactions to SC formulations.",,ALL
DENY-PED-001,Pediatric First-Line CGRP - Age-Appropriate Step Therapy,"Patient is a minor (age [X]) with migraine. Per 2024 AHS Consensus and FDA pediatric approval, CGRP monoclonal antibodies (Aimovig, Ajovy, Emgality) are approved for patients age 6 and older. Pediatric step therapy requirements should be reduced (1 oral preventive class vs adult 2) given developmental considerations and the importance of early effective treatment to prevent chronic migraine evolution. Trial duration of 4-8 weeks (vs adult 8 weeks) is clinically appropriate for pediatric patients.",AHS Consensus 2024 | FDA Pediatric Labels,FDA pediatric approvals 2023 | AHS Consensus pediatric section,Pediatric patient (6-17) requesting CGRP mAb with reduced step therapy,Pediatric-Specific Step Therapy Reduction,"Erenumab (Aimovig), Fremanezumab (Ajovy), Galcanezumab (Emgality)","Age 6-11: 1 oral preventive class failure (4-8 weeks); Age 12-17: May use adult criteria or reduced per payer. Document weight for dosing (Aimovig: 70mg if <60kg, 140mg if ≥60kg for age 12-17).",,ALL
DENY-PED-002,Pediatric Off-Label Gepant - AHS-Supported Use,"Patient is an adolescent (age 12-17) with migraine and documented contraindication to or failure of triptans. While gepants (Nurtec ODT, Ubrelvy) are FDA-approved for adults only, the 2024 AHS Consensus Statement supports their use in adolescents: 'Oral CGRP receptor antagonists are recommended as acute migraine treatment options. Clinical evidence supports use in adolescents when triptans are contraindicated or ineffective.' Off-label use is clinically appropriate and supported by major headache society guidelines.",AHS Consensus 2024,"AHS Consensus Statement 2024, Pediatric Section",Adolescent patient (12-17) requesting gepant off-label,Off-Label Gepant with AHS Support,"Rimegepant (Nurtec ODT), Ubrogepant (Ubrelvy)","Requires: (1) Documentation of ≥2 triptan failures OR triptan contraindication, (2) Medical Necessity Letter citing AHS Consensus, (3) Headache diary. Expect initial denial; prepare appeal.",,ALL
DENY-QL-001,Quantity Limit Override - High-Frequency Episodic Migraine,"Patient has high-frequency episodic migraine (≥8 migraine days/month) requiring acute treatment beyond standard quantity limits. The current limit of [X] doses per month is insufficient for clinical management. Restricting acute medication access increases risk of inadequate pain control, emergency department utilization, and progression to chronic migraine. Per ICHD-3, high-frequency episodic migraine (8-14 days/month) requires more aggressive acute management.",ICHD-3 Criteria | AHS Consensus 2021,ICHD-3 Section 1.1 | Ailani J et al. Headache. 2021,Patient needs more acute doses than standard QL allows,Quantity Limit Override for High-Frequency Migraine,"Sumatriptan, Rizatriptan, Ubrelvy, Nurtec ODT",Document monthly migraine frequency from headache diary. Standard QLs: Ubrelvy 16/30d; Nurtec 8/30d (acute). Override arguments: menstrual migraine requiring multi-day dosing; cluster-like features.,,ALL
DENY-QOL-001,Quality of Life Improvement Documentation,Patient demonstrates clinically meaningful improvement in quality of life on current migraine therapy as measured by validated instruments. MIDAS score reduction of ≥30% or HIT-6 score reduction of ≥5 points indicates clinically significant improvement. Continuation of therapy is medically necessary to maintain functional status.,ACP Guidelines 2025 | MIDAS/HIT-6 Validation Studies,Qaseem A et al. Ann Intern Med. 2025;178:426-433. | Stewart WF et al. Neurology. 2001;56(6 Suppl 1):S20-S28.,Requesting continuation or renewal with QoL documentation using MIDAS/HIT-6,Validated QoL instrument showing clinically meaningful improvement,All migraine preventive therapies,"Include baseline and current scores. MIDAS: Grade I (0-5), II (6-10), III (11-20), IV (≥21). HIT-6: ≤49 (little/no impact), 50-55 (some), 56-59 (substantial), ≥60 (severe).",,ALL
DENY-REFRAC-001,Treatment-Refractory Chronic Migraine,"Patient has treatment-refractory chronic migraine with inadequate response to migraine-specific acute therapy and multiple preventive medication classes. Refractory status is defined by failure of ≥2 preventive medication classes from different pharmacologic categories at therapeutic doses for ≥8 weeks each, with <50% reduction in monthly headache days. Advanced interventions including CGRP-targeting therapies, dual therapy, or neuromodulation are medically necessary.",AHS Consensus 2021 | ACP Guidelines 2025,Ailani J et al. Headache. 2021;61(7):1021-1039. | Qaseem A et al. Ann Intern Med. 2025;178:426-433.,Patient failed multiple preventive classes; requesting CGRP mAbs or combination therapy,Documented failure of ≥2 preventive classes at therapeutic dose for ≥8 weeks,"CGRP mAbs, Gepants, OnabotulinumtoxinA, Neuromodulation devices","Document each prior preventive trial: medication name, dose achieved, duration, reason for discontinuation. Required: ≥8 weeks at therapeutic dose per ACP 2025.",,ALL
DENY-RENEW-001,Renewal/Continuation - Sustained Reduction in Headache Days,"Patient demonstrates sustained reduction in monthly headache days on current CGRP-targeting therapy. Continuation is medically necessary to maintain therapeutic benefit and prevent disease progression. Discontinuation would result in return to baseline disability and increased healthcare utilization. Per ACP guidelines, success metric is ≥50% reduction in mean monthly headache days.",ACP Guidelines 2025 | AHS Position Statement 2024,Qaseem A et al. Ann Intern Med. 2025;178:426-433. doi:10.7326/ANNALS-24-01052,Requesting reauthorization of CGRP mAb or gepant with documented efficacy,Documented ≥50% reduction in monthly headache days,All CGRP mAbs and gepants,Document pre-treatment baseline headache frequency vs. current frequency. Include MIDAS or HIT-6 scores showing improvement.,,ALL
DENY-SERO-001,Serotonin Syndrome Risk - Triptan Contraindication with SSRIs/SNRIs,"Patient is currently prescribed [SSRI/SNRI medication] for [indication]. Per FDA Drug Safety Communication, concomitant use of triptans with SSRIs or SNRIs may result in serotonin syndrome, a potentially life-threatening condition. Given patient's psychiatric medication regimen, gepants (which have no serotonergic activity) are medically necessary as the safer acute migraine treatment option.",FDA Drug Safety Communication 2006 | AHS Consensus,FDA Drug Safety Communication: Combined Use of 5-HT1 Receptor Agonists (Triptans) and SSRIs/SNRIs,Patient on SSRI/SNRI requesting gepant to avoid serotonin syndrome risk,Serotonin Syndrome Risk Bypass,"Rimegepant (Nurtec ODT), Ubrogepant (Ubrelvy)","Document current SSRI/SNRI: fluoxetine, sertraline, paroxetine, escitalopram, duloxetine, venlafaxine, etc. Note: FDA warning is for combination; clinical risk is debated but provides valid bypass argument.",,ALL
DENY-SPEC-001,Specialty Reviewer Requirement - Invalid Denial,"Pursuant to [STATE STATUTE], an adverse determination based on medical necessity must be made by a clinical peer in the same or similar specialty as the prescribing provider. The reviewer who issued this denial does not hold board certification in Neurology or Headache Medicine. This determination is procedurally invalid. We demand immediate reversal or review by a board-certified Neurologist.",State Specialty Reviewer Statutes,NH RSA 420-J | MT HB 399 | IN SB 480 | AL 'No AI Denial' policy,Denial issued by non-specialty reviewer; challenging procedural validity,Specialty Reviewer / Clinical Peer Requirement,All migraine medications requiring specialist knowledge,"Request copy of reviewer credentials. If reviewer is Family Medicine, Pediatrics, or General IM - not Neurology - challenge is valid.","NH: 'This determination violates NH RSA 420-J by failing to utilize a statutorily required clinical peer. We demand immediate reversal or review by a board-certified Neurologist.' | MT: 'Pursuant to Montana HB 399, Section 1(2), an adverse determination must be made by a physician whose specialty focuses on the diagnosis and treatment of the condition. The reviewer does not hold board certification in Neurology. This determination is procedurally invalid.' | IN: 'Pursuant to Indiana SB 480, peer review must be conducted by same specialty.' | AL: 'Pursuant to Alabama Insurance Department policy, denials based solely on AI/algorithmic review without physician oversight are invalid.'","NH,MT,IN,AL,NE"
DENY-STEP-001,Step Therapy Required - Triptan Failure for Gepants/Ditans,"Patient has a contraindication to vasoconstrictive agents. Triptans and ergotamines are vasoconstrictors and are contraindicated in patients with history of uncontrolled hypertension, ischemic heart disease, peripheral vascular disease, cerebrovascular disease, or hemiplegic/basilar migraine. The mechanism of action of Gepants (Ubrelvy/Nurtec) and Ditans (Reyvow) does not involve vasoconstriction, establishing them as the medically necessary first-line acute treatment for this patient to prevent adverse cardiovascular events.",AHS Consensus 2021 | ACP Guidelines 2025,Ailani J et al. Headache. 2021;61(7):1021-1039. doi:10.1111/head.14153,Requesting Ubrelvy/Nurtec/Reyvow when patient has documented cardiovascular contraindications to triptans,Cardiovascular Disease / Uncontrolled Hypertension bypass,"Ubrogepant (Ubrelvy), Rimegepant (Nurtec ODT), Lasmiditan (Reyvow)","Use ONLY when documented CV contraindications exist in medical record. Required documentation: diagnosis of CAD, PVD, uncontrolled HTN, CVA history, or hemiplegic/basilar migraine subtype.",,ALL
DENY-STEP-002,Step Therapy Required - Oral Preventive Failure for Non-Oral Formulations,"Patient has severe gastrointestinal intolerance with documented gastroparesis/gastric stasis preventing absorption of oral medications. Oral acute and preventive medications are clinically inappropriate due to impaired gastric motility. Non-oral formulations (nasal spray, subcutaneous injection, IV infusion, neuromodulation devices) are medically necessary to achieve therapeutic effect.",AHS Consensus 2021 | ACP Guidelines 2025,Ailani J et al. Headache. 2021;61(7):1021-1039. doi:10.1111/head.14153,Requesting injectable CGRP mAbs or nasal DHE when patient cannot tolerate oral medications,Severe Nausea/Vomiting (Gastric Stasis) bypass,"Erenumab (Aimovig), Fremanezumab (Ajovy), Galcanezumab (Emgality), Eptinezumab (Vyepti), DHE nasal spray (Trudhesa), Neuromodulation devices",Use when patient has documented gastroparesis diagnosis or severe nausea/vomiting during migraine attacks preventing oral medication use. ICD-10: K31.84 (Gastroparesis).,,ALL
DENY-STEP-003,Step Therapy Required - Teratogenic Medication Bypass,Patient has teratogenic contraindication to valproate and topiramate. These medications must not be prescribed to women of childbearing potential without reliable birth control due to established teratogenic risks and birth defects. CGRP monoclonal antibodies and gepants represent safer alternatives for migraine prevention in this population.,AHS Consensus 2019 | ACP Guidelines 2025 | FDA Black Box Warning,American Headache Society. Headache. 2019;59(1):1-18. doi:10.1111/head.13456,Requesting CGRP mAbs or gepants for female patient of childbearing potential when valproate/topiramate would otherwise be indicated,Pregnancy / Childbearing Potential bypass,"Erenumab (Aimovig), Fremanezumab (Ajovy), Galcanezumab (Emgality), Atogepant (Qulipta), Rimegepant (Nurtec ODT)",Use for females of childbearing age (typically 15-50) regardless of current pregnancy status. Document reproductive status and contraception discussion in chart.,,ALL
DENY-STEP-004,Step Therapy Required - MOH Risk Prevention,"Patient is at high risk for Medication Overuse Headache (MOH) due to current acute medication use exceeding 2 days per week. Opioids, butalbital-containing compounds, and non-specific analgesics carry significant MOH risk. CGRP-targeting therapies (gepants for acute use, mAbs for prevention) do not carry the same MOH risk profile and are medically necessary to break the cycle of medication overuse while providing effective migraine treatment.",AHS Consensus 2021 | ICHD-3 Criteria,Ailani J et al. Headache. 2021;61(7):1021-1039. | ICHD-3 Chapter 8.2,Patient using acute medications >10-15 days/month at risk for or currently experiencing MOH; requesting gepants or CGRP mAbs,Risk of Medication Overuse Headache (MOH) bypass,"Rimegepant (Nurtec ODT), Ubrogepant (Ubrelvy), Erenumab (Aimovig), Fremanezumab (Ajovy), Galcanezumab (Emgality)","Document frequency of acute medication use in headache diary. ICHD-3 MOH thresholds: Simple analgesics ≥15 days/month, Triptans/ergots/opioids/combination ≥10 days/month. ICD-10: G44.41.",,ALL
DENY-STEP-005,Step Therapy Required - Adverse Event Intolerance,"Patient experienced discontinuation due to adverse events from topiramate and/or tricyclic antidepressants. Topiramate is associated with high rates of adverse events including paresthesia, cognitive slowing ('brain fog'), weight loss, and nephrolithiasis leading to discontinuation. TCAs cause anticholinergic effects, sedation, and cardiac conduction abnormalities. ACP guidelines prioritize treatments with favorable adverse event profiles. CGRP-targeting therapies demonstrate remarkable tolerability with significantly lower discontinuation rates.",AHS Position Statement 2024 | ACP Guidelines 2025,Charles AC et al. Headache. 2024;64(4):333-341. doi:10.1111/head.14692,Patient failed topiramate or TCA due to intolerable side effects; requesting CGRP mAbs or gepants,Adverse Event Intolerance (Cognitive/Physical) bypass,"Erenumab (Aimovig), Fremanezumab (Ajovy), Galcanezumab (Emgality), Atogepant (Qulipta)","Document specific adverse events experienced and duration of trial before discontinuation. Common topiramate AEs: paresthesia, cognitive dysfunction, weight loss, kidney stones. Common TCA AEs: dry mouth, constipation, sedation, weight gain, QT prolongation.",,ALL
DENY-SWITCH-001,Non-Medical Switching Defense - Stable Patient,"Patient is stable on [current medication] and has achieved therapeutic benefit. Switching a patient who has achieved therapeutic stability on a specific CGRP monoclonal antibody solely for non-medical (formulary) reasons is clinically inadvisable and may result in rebound disability. Per AHS 2024 Consensus, non-medical switching of stable migraine patients is not recommended and may constitute a coverage violation under state continuity of care protections.",AHS Consensus 2021 | State Continuity Statutes,Ailani J et al. Headache. 2021;61(7):1021-1039. | NH Harvard Pilgrim Ajovy scenario,Payer requiring switch from effective medication to formulary alternative,Non-Medical Switching / Therapeutic Stability Defense,All CGRP mAbs (Aimovig/Ajovy/Emgality switching scenarios),"Document: (1) Duration on current therapy, (2) Response metrics (headache day reduction, MIDAS/HIT-6), (3) Stability statement. Use MOA argument if switching between receptor blocker (Aimovig) and ligand binders (Ajovy/Emgality).","NH (Harvard Pilgrim Ajovy): 'Patient is stable on Fremanezumab, which targets the CGRP ligand. The preferred alternative, Erenumab (Aimovig), targets the receptor. These are pharmacologically distinct mechanisms. Switching a stable responder from a ligand-binder to a receptor-blocker carries documented risk of loss of efficacy.'","NH,ALL"
DENY-TIME-001,Deemed Approved - Statutory Timeline Violation,"Pursuant to [STATE STATUTE], the statutory window for prior authorization determination has lapsed. This PA request was submitted on [DATE/TIME] - see attached timestamp. Under state law, failure to render a timely decision results in the request being 'deemed approved' by operation of law. We are proceeding with treatment and expect payment in full. Denial of this claim will result in a complaint filed with the state Insurance Department.",State PA Timeline Statutes,NH SB 561 | MS SB 2140 | NE LB 77 | OK HB 3190,Payer failed to respond within statutory timeframe; asserting automatic approval,Deemed Approved / Auto-Approval on Timeline Violation,All medications subject to PA,Document exact submission timestamp and statutory deadline. File complaint with state Insurance Department if payer disputes.,"NH: 'Pursuant to NH RSA 420-J:7-b (SB 561), pharmacy PA decisions must be rendered within 2 business days. This deadline has passed. The drug is deemed approved by operation of law.' | MS: 'Pursuant to MS Code § 83-9-6.3 (SB 2140), this PA is deemed authorized after [2 biz days pharma / 7 days medical].' | NE: 'Pursuant to Nebraska LB 77, the 72-hour urgent decision window has lapsed.' | OK: 'Pursuant to Oklahoma HB 3190, failure to respond within 72 hours for urgent requests deems the service authorized.'","NH,MS,NE,OK"
